Skip to main content

Table 1 Phenotypes and genotypes of sequential LES isolates from six CF patients

From: Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain

Patient

Year

Isolate

PFGE

Pyocyanin (OP phenotype)

LasA{SD}

lasR mut.

CAZ

MER

ATM

TOB

CIP

Colony morphology

A

1995

B7

I-II

+

24.2 {4.9}

NO

R

R

R

D

D

SCV,NM,Ra,S

A

1998

B32

I-II

-

98.4 {7.2}

YES

S

R

S

D

S

SCV,NM,F,S

A

2000

B45

ID-II

-

67.3 {1.9}

nd

R

R

R

R

S

NM,F,S

A

2003

B25

I-II

-

98.6 {0.6}

YES

S

R

S

S

S

NM,Ra,S

A

2003

B70

IC-II

-

82.7 {5.1}

NO

R

R

R

S

S

M,Ra,S

A

2004

49111

ND

-

98.7 {1.6}

YES

S

R

S

S

S

NM,Ra,RW

A

2004

49074

ND

-

97.0 {1.5}

YES

R

R

R

S

S

NM,Ra,S

B

1996

B46

IH-IIE

+

81.6 {2.2}

NO

R

R

R

D

D

SCV,NM,F,S

B

1998

B38

I-II

+

84.8 {2.9}

NO

R

R

R

D

S

NM,Ra,S

B

2003

B60

IE-II

+

20.6 {1.9}

nd

R

R

R

D

S

NM,F,S

B

2003

B48

I-II

-

93.2 {0.9}

NO

S

R

R

S

S

M,Ra,S

B

2004

49194

ND

-

93.6 {0.9}

NO

S

S

S

S

R

NM,Ra,S

C

1996

B49

IC-II

+

43.3 {4.4}

nd

R

R

S

S

S

SCV,NM,F,S

C

1998

B40

I-II

+

20.3 {2.3}

nd

S

R

S

R

S

SCV,NM,F,S

C

1998

B41

I-II

-

98.6 {1.3}

YES

S

R

S

D

S

NM,Ra,S

C

1998

109

ND

+

82.7 {1.1}

nd

S

S

S

S

S

NM,F,S

C

2003

B64

I-II

-

95.2 {1.8}

NO

S

S

S

S

D

SCV,NM,F.S

C

2003

B65

I-II

+

8.61 {7.8}

nd

S

R

S

D

S

NM,Ra,S

C

2004

49137

ND

INT

63.4 {3.4}

nd

S

S

S

D

R

SCV,NM,F,S

D

1996

B28

IC-II

-

41.3 {5.5}

NO

S

R

S

S

S

SCV,NM,F,S

D

1998

B35

IC-II

INT

96.6 {1.2}

NO

S

S

S

D

S

SCV,NM,F,S

D

2002

B61

IC-II

NOR

3.33 {4.4}

nd

R

R

S

R

D

NM,Ra,S

D

2002

B62

I-IIG

-

95.3 {5.4}

YES

S

S

S

S

S

SCV,NM,F,S

D

2002

B63

I-II

-

98.5 {1.9}

YES

S

R

S

R

S

NM,Ra,S

E

1995

B4

IC-II

-

95.2 {2.0}

YES

S

S

S

R

S

NM,Ra,S

E

1995

B57

I-II

+

26.8 {3.2}

NO

R

R

R

S

D

NM,Ra,S

E

2000

B50

I-II

-

96.4 {3.6}

NO

R

R

R

S

S

M,Ra,S

E

2000

B51

I-II

-

98.4 {2.6}

YES

S

S

S

R

S

SCV,NM,Ra,S

E

2002

B67

ID-IIB

-

98.4 {2.9}

YES

R

R

R

S

D

NM,F,S

F

1996

B30

I-II

-

98.5 {1.0}

YES

S

S

R

R

S

SCV,NM,Ra,S

F

2000

B55

I-II

NOR

34.8 {4.4}

nd

S

S

S

S

S

M,Ra,S

F

2002

B68

IA-II

NOR

88.5 {4.4}

nd

S

S

S

S

S

NM,F,S

F

2002

B69

IB-IID

+

31.6 {5.6}

nd

R

R

R

R

S

NM,F,S

  1. PFGE refers to pulsotypes obtained with Spe I and Xba I respectively; LasA activity indicates the percentage of the initial (time zero) A600 value remaining after 60 min; SD: standard deviation for four replicates; lasR mut. refers to whether the isolate is a confirmed lasR mutant or not by sequencing; ND: not determined; antimicrobial agent abbreviations are ceftazidime (CAZ), aztreonam (ATM), meropenem (MER), tobramycin (TOB) and ciprofloxacin (CIP); colony morphology was scored as mucoid (M), non-mucoid (NM), flat (F) raised (Ra), smooth (S), rough/wrinkled (RW), small colony variant (SCV). For OP phenotype: + indicates OP-positive; - indicates OP-negative; INT indicates intermediate; NOR indicates normal.